CA3044270A1 - The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____ - Google Patents
The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____ Download PDFInfo
- Publication number
- CA3044270A1 CA3044270A1 CA3044270A CA3044270A CA3044270A1 CA 3044270 A1 CA3044270 A1 CA 3044270A1 CA 3044270 A CA3044270 A CA 3044270A CA 3044270 A CA3044270 A CA 3044270A CA 3044270 A1 CA3044270 A1 CA 3044270A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- trimetazidine
- patient
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424771P | 2016-11-21 | 2016-11-21 | |
| US62/424,771 | 2016-11-21 | ||
| PCT/US2017/062771 WO2018094387A1 (en) | 2016-11-21 | 2017-11-21 | Prevention and/or treatment of contrast-induced acute kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3044270A1 true CA3044270A1 (en) | 2018-05-24 |
Family
ID=62144125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3044270A Pending CA3044270A1 (en) | 2016-11-21 | 2017-11-21 | The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____ |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20180140599A1 (enExample) |
| EP (2) | EP4378457A3 (enExample) |
| JP (3) | JP7474463B2 (enExample) |
| CA (1) | CA3044270A1 (enExample) |
| MX (1) | MX2019005782A (enExample) |
| WO (1) | WO2018094387A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4378457A3 (en) * | 2016-11-21 | 2024-07-31 | Saghmos Therapeutics, Inc. | Prevention and/or treatment of contrast-induced acute kidney injury |
| WO2019161309A1 (en) * | 2018-02-19 | 2019-08-22 | Martin Pharmaceuticals Inc. | Stable oral liquid formulation of trimetazidine |
| WO2025137462A1 (en) * | 2023-12-21 | 2025-06-26 | Numiera Therapeutics Inc. | Combination therapy for cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2490963B1 (fr) * | 1980-09-30 | 1986-04-18 | Science Union & Cie | Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine |
| US20080059228A1 (en) | 2004-04-24 | 2008-03-06 | Christopher Bossi | Operation Of A Remote Medication Management System |
| US20100266501A1 (en) * | 2006-11-07 | 2010-10-21 | University Of Vermont and State Agricltural College | Methods and compositions for organ protection |
| WO2008111956A2 (en) | 2007-03-09 | 2008-09-18 | Symcopeia Company | Fatty acid oxidation inhibitors treating hyperglycemia and related disorders |
| EP2187874A2 (en) * | 2007-08-08 | 2010-05-26 | Usv Limited | Sustained release compositions of trimetazidine and process for preparation thereof |
| WO2009034541A2 (en) | 2007-09-11 | 2009-03-19 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical dosage forms of trimetazidine |
| US20090257999A1 (en) * | 2007-12-31 | 2009-10-15 | Inotek Pharmaceuticals Corporation | Method of preventing contrast-induced nephropathy |
| US8143219B2 (en) * | 2008-02-26 | 2012-03-27 | Cornell University | Methods for prevention and treatment of acute renal injury |
| JP2013506681A (ja) | 2009-10-02 | 2013-02-28 | バクスター・インターナショナル・インコーポレイテッド | 腎損傷の処置における使用のための造血幹細胞 |
| US9271952B2 (en) | 2011-10-11 | 2016-03-01 | Complexa, Inc. | Compositions and methods for treating nephropathy |
| FR2986431B1 (fr) * | 2012-02-03 | 2017-03-17 | Servier Lab | Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques |
| EP4378457A3 (en) | 2016-11-21 | 2024-07-31 | Saghmos Therapeutics, Inc. | Prevention and/or treatment of contrast-induced acute kidney injury |
| US20180190374A1 (en) | 2017-01-03 | 2018-07-05 | Saghmos Therapeutics, Inc. | Methods of improving patient compliance to treat contrast-induced injury |
-
2017
- 2017-11-21 EP EP24155776.8A patent/EP4378457A3/en active Pending
- 2017-11-21 CA CA3044270A patent/CA3044270A1/en active Pending
- 2017-11-21 US US15/819,591 patent/US20180140599A1/en not_active Abandoned
- 2017-11-21 MX MX2019005782A patent/MX2019005782A/es unknown
- 2017-11-21 WO PCT/US2017/062771 patent/WO2018094387A1/en not_active Ceased
- 2017-11-21 JP JP2019547594A patent/JP7474463B2/ja active Active
- 2017-11-21 EP EP17872053.8A patent/EP3525771A4/en not_active Withdrawn
- 2017-11-21 US US16/462,789 patent/US11123345B2/en active Active
-
2021
- 2021-09-14 US US17/475,212 patent/US11986473B2/en active Active
-
2022
- 2022-02-17 JP JP2022022785A patent/JP2022059054A/ja active Pending
-
2024
- 2024-01-26 JP JP2024010111A patent/JP2024028652A/ja active Pending
- 2024-04-05 US US18/627,978 patent/US20250073227A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022059054A (ja) | 2022-04-12 |
| US20190365740A1 (en) | 2019-12-05 |
| EP4378457A3 (en) | 2024-07-31 |
| US20250073227A1 (en) | 2025-03-06 |
| US11986473B2 (en) | 2024-05-21 |
| MX2019005782A (es) | 2019-08-29 |
| JP2024028652A (ja) | 2024-03-04 |
| EP3525771A4 (en) | 2020-05-27 |
| EP4378457A2 (en) | 2024-06-05 |
| JP2019535830A (ja) | 2019-12-12 |
| WO2018094387A1 (en) | 2018-05-24 |
| US20210401832A1 (en) | 2021-12-30 |
| US20180140599A1 (en) | 2018-05-24 |
| JP7474463B2 (ja) | 2024-04-25 |
| EP3525771A1 (en) | 2019-08-21 |
| US11123345B2 (en) | 2021-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250073227A1 (en) | Prevention and/or treatment of contrast-induced acute kidney injury | |
| JP7697885B2 (ja) | 化合物の製剤およびそれらの使用 | |
| RS53491B1 (sr) | Kompozicije za lečenje centralno posredovane mučnine i povraćanja | |
| EA015122B1 (ru) | Фармацевтическая композиция и ее применение для лечения тромбоза | |
| JP2014534270A5 (enExample) | ||
| JP2018531605A5 (enExample) | ||
| KR20120138229A (ko) | 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료 | |
| KR20120089623A (ko) | 정맥내 투여용 이부프로펜을 이용한 환자의 치료 | |
| HK40112570A (en) | Prevention and/or treatment of contrast-induced acute kidney injury | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| JP6073202B2 (ja) | 静脈におけるウイルスの治療 | |
| EP1893205A2 (en) | Dosage regimen for prasugrel | |
| JP2018537522A (ja) | 組合せ | |
| WO2018129045A1 (en) | Methods of improving patient compliance to treat contrast-induced injury | |
| EP4185291B1 (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| JP7618235B2 (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法 | |
| JP2012087082A (ja) | 血栓若しくは塞栓によって引き起こされる疾病の予防又は治療用医薬組成物 | |
| JP2009538822A5 (enExample) | ||
| JP2016510738A5 (enExample) | ||
| JP2006510613A (ja) | ３，７−ジアザビシクロ［３．３．１］ノナン化合物を含有する液体医薬組成物および抗不整脈事象に関する治療法 | |
| Vet—QC09CA02 | Eprosartan Mesilate (BANM, rINNM) | |
| Rahman | A clinically oriented review of the landmark clinical trials comparing warfarin and aspirin to novel oral anticoagulants in atrial fibrillation | |
| WO2022147318A1 (en) | Methods of treatment | |
| RS53161B (sr) | Tečna farmaceutska smeša nifedipina za oralnu upotrebu | |
| US20190262357A1 (en) | Preventative or therapeutic agent for pulmonary hypertension including crude drug component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| EEER | Examination request |
Effective date: 20220921 |
|
| EEER | Examination request |
Effective date: 20220921 |
|
| EEER | Examination request |
Effective date: 20220921 |
|
| EEER | Examination request |
Effective date: 20220921 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241023 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241023 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241023 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241230 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED Effective date: 20250423 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250820 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250820 |